Skip to main content
OpenTrials
Completed

NCT Number: NCT00546182

Simvastatin Reduces Adiponectin Levels and Insulin Sensitivity

We hypothesized simvastatin may reduce adiponectin levels and insulin sensitivity in overweight hypercholesterolemic patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypercholesterolemia Dyslipidemias Glucose Metabolism Disorders Hyperinsulinism Hyperlipidemias Insulin Resistance Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

25 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Gil Medical Center, Gachon University

Incheon, 405760, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Low-density lipoprotein cholesterol levels more than 100 and body mass index more than 23.0

Exclusion criteria

  • Patients with overt liver disease
  • Chronic renal failure
  • Hypothyroidism, myopathy
  • Uncontrolled diabetes
  • Severe hypertension, stroke
  • Acute coronary events
  • Coronary revascularization within the preceding 3 months, or
  • Alcohol abuse.

Treatment and study plan

Primary outcomes

  1. simvastatin may reduce adiponectin levels and insulin sensitivity in overweight hypercholesterolemic patients

Sponsors and collaborators

Lead sponsor

Gachon University Gil Medical Center

Other

Registry information

Official study title

Phase 4 Study of Simvastatin That Affects Insulin Sensitivity

Important dates

Study start
2004
First posted
Oct 18, 2007
Registry last updated
Oct 18, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.